Pharmacokinetic and In Vivo Efficacy Studies of the Mycobactin Biosynthesis Inhibitor Salicyl-AMS in Mice

ABSTRACT Mycobactin biosynthesis in Mycobacterium tuberculosis facilitates iron acquisition, which is required for growth and virulence. The mycobactin biosynthesis inhibitor salicyl-AMS [5′-O-(N-salicylsulfamoyl)adenosine] inhibits M. tuberculosis growth in vitro under iron-limited conditions. Here, we conducted a single-dose pharmacokinetic study and a monotherapy study of salicyl-AMS with mice. Intraperitoneal injection yielded much better pharmacokinetic parameter values than oral administration did. Monotherapy of salicyl-AMS at 5.6 or 16.7 mg/kg significantly inhibited M. tuberculosis growth in the mouse lung, providing the first in vivo proof of concept for this novel antibacterial strategy.

[1]  M. Niederweis,et al.  Discovery of a Siderophore Export System Essential for Virulence of Mycobacterium tuberculosis , 2013, PLoS pathogens.

[2]  C. Aldrich,et al.  Development of a selective activity-based probe for adenylating enzymes: profiling MbtA Involved in siderophore biosynthesis from Mycobacterium tuberculosis. , 2012, ACS chemical biology.

[3]  Che L. Martin,et al.  Mutational and Phylogenetic Analyses of the Mycobacterial mbt Gene Cluster , 2011, Journal of bacteriology.

[4]  H. Derendorf,et al.  PA-824 Exhibits Time-Dependent Activity in a Murine Model of Tuberculosis , 2010, Antimicrobial Agents and Chemotherapy.

[5]  C. Aldrich,et al.  Antitubercular nucleosides that inhibit siderophore biosynthesis: SAR of the glycosyl domain. , 2006, Journal of medicinal chemistry.

[6]  C. Aldrich,et al.  Rationally designed nucleoside antibiotics that inhibit siderophore biosynthesis of Mycobacterium tuberculosis. , 2006, Journal of medicinal chemistry.

[7]  Derek S. Tan,et al.  Small-molecule inhibition of siderophore biosynthesis in Mycobacterium tuberculosis and Yersinia pestis , 2005, Nature chemical biology.

[8]  Gilla Kaplan,et al.  Differential expression of iron-, carbon-, and oxygen-responsive mycobacterial genes in the lungs of chronically infected mice and tuberculosis patients , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[9]  H. Su,et al.  The salicylate-derived mycobactin siderophores of Mycobacterium tuberculosis are essential for growth in macrophages. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[10]  C. Walsh,et al.  Identification of a Mycobacterium tuberculosis gene cluster encoding the biosynthetic enzymes for assembly of the virulence-conferring siderophore mycobactin. , 1998, Chemistry & biology.

[11]  L. Collins,et al.  Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium , 1997, Antimicrobial agents and chemotherapy.

[12]  M. Horwitz,et al.  Exochelins of Mycobacterium tuberculosis remove iron from human iron- binding proteins and donate iron to mycobactins in the M. tuberculosis cell wall , 1996, The Journal of experimental medicine.

[13]  C. H. Moore,et al.  Iron acquisition by Mycobacterium tuberculosis: isolation and characterization of a family of iron-binding exochelins. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[14]  C. Ratledge,et al.  Extracellular iron acquisition by mycobacteria: role of the exochelins and evidence against the participation of mycobactin , 1975, Infection and immunity.